Aisling Capital Management’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-615,352
| Closed | -$65.7M | – | 15 |
|
|
2025
Q3 | $65.7M | Hold |
615,352
| – | – | 14.39% | 2 |
|
|
2025
Q2 | $58.2M | Hold |
615,352
| – | – | 16.18% | 2 |
|
|
2025
Q1 | $39.1M | Sell |
615,352
-500,000
| -45% | -$29.9M | 13.54% | 2 |
|
|
2024
Q4 | $51.8M | Hold |
1,115,352
| – | – | 18.38% | 2 |
|
|
2024
Q3 | $32.1M | Hold |
1,115,352
| – | – | 12.29% | 2 |
|
|
2024
Q2 | $16.1M | Hold |
1,115,352
| – | – | 6.98% | 3 |
|
|
2024
Q1 | $17.9M | Hold |
1,115,352
| – | – | 6.07% | 3 |
|
|
2023
Q4 | $22.2M | Hold |
1,115,352
| – | – | 6.61% | 2 |
|
|
2023
Q3 | $18.2M | Hold |
1,115,352
| – | – | 7.49% | 2 |
|
|
2023
Q2 | $23.6M | Hold |
1,115,352
| – | – | 11.55% | 2 |
|
|
2023
Q1 | $22.4M | Sell |
1,115,352
-217,133
| -16% | -$4.69M | 10.78% | 3 |
|
|
2022
Q4 | $34.8M | Hold |
1,332,485
| – | – | 22.99% | 2 |
|
|
2022
Q3 | $13.6M | Hold |
1,332,485
| – | – | 9.04% | 3 |
|
|
2022
Q2 | $5.58M | Hold |
1,332,485
| – | – | 3.98% | 7 |
|
|
2022
Q1 | $6.65M | Hold |
1,332,485
| – | – | 3.59% | 9 |
|
|
2021
Q4 | $8.95M | Hold |
1,332,485
| – | – | 3.16% | 9 |
|
|
2021
Q3 | $7.3M | Hold |
1,332,485
| – | – | 1.46% | 12 |
|
|
2021
Q2 | $8.71M | Hold |
1,332,485
| – | – | 1.4% | 15 |
|
|
2021
Q1 | $11.1M | Hold |
1,332,485
| – | – | 2.01% | 9 |
|
|
2020
Q4 | $9.33M | Hold |
1,332,485
| – | – | 1.6% | 9 |
|
|
2020
Q3 | $8.31M | Buy |
1,332,485
+888,889
| +200% | +$6.14M | 2.66% | 8 |
|
|
2020
Q2 | $2.07M | Hold |
443,596
| – | – | 0.79% | 11 |
|
|
2020
Q1 | $1.83M | Hold |
443,596
| – | – | 0.8% | 11 |
|
|
2019
Q4 | $2.55M | Hold |
443,596
| – | – | 0.98% | 11 |
|
|
2019
Q3 | $2.03M | Hold |
443,596
| – | – | 1.06% | 12 |
|
|
2019
Q2 | $2.26M | Hold |
443,596
| – | – | 0.97% | 13 |
|
|
2019
Q1 | $2.88M | Hold |
443,596
| – | – | 2.2% | 12 |
|
|
2018
Q4 | $4.28M | Buy |
+443,596
| New | +$5.04M | 4.51% | 9 |
|
Other funds holding VRNA
Aisling Capital Management's VRNA Position: Q4 2025 in Review
Aisling Capital Management sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 615,352 shares — an estimated $65.7M sold.
Aisling Capital Management first reported a position in VRNA in Q4 2018 and held it in 28 quarters. The position peaked at $65.7M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Aisling Capital Management reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Aisling Capital Management sold 615,352 Verona Pharma shares in Q4 2025, an estimated $65.7M.
- Aisling Capital Management first reported a position in Verona Pharma in Q4 2018 and held it in 28 quarters.
- Aisling Capital Management's Verona Pharma position peaked at $65.7M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Aisling Capital Management's 13F filing for Q4 2025, filed 10 Feb 2026.